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Discussion
Limitations
Figure 1. Shark Core fine needle biopsy system with 6 beveled cutting edge surface to 
decrease tissue fracturing and penetration force while maintaining intact tissue structure. 
•  Sharkcore Fine Needle Biopsy (FNB) 
system allows for interchangeability 
of all needle sizes through a 
universal delivery system for rapid 
needle exchange and passes 
and for the possible collection of 
histological samples. 
•  Studies suggest that diagnostic 
accuracy/adequacy can be 
enhanced with the use of rapid 
onsite evaluation (ROSE). 
•  Advantage of FNB vs FNA 
  –  Accurate diagnosis of an 
otherwise undifferentiated tumor 
with tissue acquisition
  –  Options involving surgical and 
oncologic care can be guided by 
the results
  –  Prevent inappropriate treatment
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•  Small sample size (n = 33), single center
•  Short time period (6 months) for both 
advanced endosonographers to access and 
train with new FNB system
•  Pathology protocol for core tissue biopsies
Future Studies
•  Utilizing this technology for intra-thoracic 
malignancy 
•  Comparing ROSE adequacy with final pathology
•  If increase familiarity with the system decreases 
the need for ROSE
•  Change in how samples are processed by 
pathology
•  Adequacy of samples determined by final pathological read was 87.9%.
  –  Factors to increase adequacy in sampling are ROSE availability, experience of the endosonographer and 
familiarity or continued exposure to EUS procedures.5-7
•  Our study indicated, based on the pathology protocol, that this needle system did not provide core 
tissue samples.
  –  Majority of samples underwent histological processing, but were done so as an afterthought. 
  –  One study reviewed the use of both FNA and FNB systems to obtain histological samples and revealed 
the FNB to be unsatisfactory in yielding core specimen compared to the FNA system.8
•  ROSE allows real time feedback to endosonographers to assist in adequacy samples for biological 
sampling with about a 10-15% increase in specimen yield in at least solid pancreatic masses.3
  –  96.2% of cases were able to obtain adequate sample, but with ROSE absent, a majority of cases were 
still found to have adequate samples. 
•  Adequacy based on location of mass 
  –  Majority of cases were sampled from pancreas with an adequacy rate of 84.2%.
  –  Intra-abdominal lymph nodes, hepatic masses and biliary samples had 100% adequacy rate but were a 
low sample size 
  –  Our study is different in that it evaluates many different pathological sites not limited to solid pancreatic 
masses that are showing adequate sampling with the use of the SharkCore FNB system.
Materials and Methods
•  Study type: 
  –  Retrospective, hypothesis-generating study conducted at a large, tertiary, single center 
teaching hospital for 6 months.
•  Equipment and Endoscopic Ultrasound (EUS) Procedure: 
  –  Patients monitored under anesthesia care with procedures performed using a linear array 
echoendoscope in left lateral decubitus position.  EUS guided FNB was done with the 22G and 25G 
FNB needle of stainless steel (ID 0.020”, 0.014 “and OD 0.028” and 0.020”), respectively. 
  –  Localization of mass followed by needle puncture, stylet removed, and needle moved to-and-fro 
within the lesion four times.  All tissue sampling performed with slow pull technique.4 Specimen then 
expressed onto slides by flushing air into needle assembly.
•  Sampling Process: 
  –  Sample is obtained from needle onto two slides, one for Diff Quick staining, one Papanicolaou stain.
    •  If core biopsy present, tissue material placed into a formalin container.
  –  Samples that not evaluated with ROSE were collected and sent directly to the pathology 
department. 
    •  Initial adequacy during ROSE determined by cytotechnologist and final adequacy verified by 
final pathology report.
    •  Adequacy based on cells appearing to be malignant or a different architecture compared to 
normal tissue.
  –  All biopsy needles are rinsed in CytoLyt. 
    •  If thick tissue fragments present, cell block for histological processing was created.
•  Statistical analysis: 
  –  The analysis was purely descriptive and exploratory in nature with descriptive statistics presented for 
the entire sample as a whole.  
  –  Means presented with the standard deviation for the continuous variables (age) 
  –  Percentages given for all cases that resulted in an adequate tissue sample overall and broken down 
by location of the mass.  
Study Aims
•  Assess the adequacy of tissue 
samples obtained from the 
SharkCore FNB 
•  Determine if location of the mass/
lesion effects adequacy 
•  Assess if ROSE is necessary in 
assisting with adequacy
•  Determine if the SharkCore FNB 
system can produce core tissue 
specimens for histological sampling
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Results
* Some percentages may not equal 100% due to rounding. 
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Table 1. FNB Background
 Indications for FNB1 Contraindications1 Complications2-3
  •  Pancreatic mass
  •  Cystic lesion with solid 
components
  •  Mediastinal lymph node 
and/or mass 
  •  Retroperitoneal lymph 
node and/or mass
  •  Perirectal lymph node 
and/or mass
  •  Lesion(s) in the left liver 
lobe
  •  Left adrenal mass
  •  Intestinal/gastric 
Subepithelial mass/lesion 
  •  Severe 
thrombocytopenia
  •  Severe coagulopathies 
  •  Inability to properly 
visualize lesion/mass 
  •  Pancreatitis 
  •  Post procedure 
hypotension
  •  Seizure
  •  Laryngospasm 
  •  Post procedural 
abdominal pain
 
 Study Inclusion Criteria Exclusion Criteria
Age > 18 years old Untreated coagulopathy
Pancreatic, hepatic, gastric, intra-abdominal or mediastinal 
mass seen on prior imaging (CT, MRI or EGD) Active pancreatitis
Masses/lesions were accessible with 19g, 22g or 25g needle Biopsies performed utilizing a different FNA system
Mass/lesion composed of some solid components
Mass/lesion felt not to be safely 
accessibleEUS-FNB performed by one of two advanced 
endosonographers
Table 3. ROSE EUS-FNB Adequacy Compared with Non ROSE EUS-FNB
   ROSE Present ROSE Absent
FNB Adequacy
Adequate 25 (96.2%) 4 (57.1%)
Inadequate 1 (3.8%) 2 (28.6%)
Less than optimal 0 (0.0%) 1 (14.3%)
Total Patients (n) 26 7
Table 4. Adequacy Based on Location of Mass
FNB Adequacy




   •  Head
   •  Body















Lymph Node 6 (100%) 0 (0.0%) 0 (0.0%) 6
Hepatic 2 (100%) 0 (0.0%) 0 (0.0%) 2
Gastric/Submucosa 3 (75.0%) 1 (25.0%) 0 (0.0%) 4
 Biliary 2 (100%) 0 (0.0%) 0 (0.0%) 2
Table 2. Clinical Characteristics of Patients
Variable  Patients (n=33)
Average Age +SD, yrs 63.3 ± 16.8
Sex
   •  Male




   •  Caucasian
   •  African American





   •  Pancreas
         –  Head
         –  Body
         –  Tail
   •  Intra-abdominal lymph node
   •  Hepatic
   •  Gastric/Submucosa
   •  Biliary
19 (57.6%)
            8 (24.2%)
            9 (27.3%)






   •  Inadequate
   •  Adequate





   •  Benign/Non-malignant
   •  Malignant
   •  Inconclusive
12 (36.4%)
16 (48.5%)
5 (15.2%)
Background
